SCHEMBL8295374

SCHEMBL8295374

CCOC(=O)c1cnc(-c2ccccc2OC)nc1Cl

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.74
KDM4E B2RXH2 1/20 0.74
MAPT P10636 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
LMNA P02545 3/20 0.50
MAPK1 P28482 1/20 0.50
ATM Q13315 1/20 0.50
TP53 P04637 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CYP1A2 P05177 2/20 0.47
POLB P06746 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125277 0.87 ALDH1A1 (0.76) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL3164274 0.86 ALDH1A1 (0.80) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL12929336 0.86 ALDH1A1 (0.68) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL8294631 0.85 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL12929695 0.84 ALDH1A1 (0.53) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL12929593 0.84 ALDH1A1 (0.69) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL12929539 0.83 ALDH1A1 (0.54) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL12929575 0.83 ALDH1A1 (0.56) ALDH1A1KDM4EMAPTSMN1; SMN2LMNA
SCHEMBL12929730 0.82 MEN1 (0.57) ALDH1A1KDM4EMAPTLMNAMAPK1
SCHEMBL12929580 0.82 MEN1 (0.56) ALDH1A1KDM4EMAPTLMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 US disclosed
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 US disclosed
WO-2005003099-A2 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS KCNJ1, KCNJ11, TRPV1 ALDH1A1 2361/4885KDM4E 1948/4885MAPT 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.